2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors

US10202365B2 · kind B2 · utility

Assignee

• Blueprint Medicines Corporation · US

Inventors

• Natasja Brooijmans · Boston, US
• Lucian V. DiPietro · Gloucester, US
• Paul E. Fleming · Wellesley, US
• Joseph L. Kim · Wayland, US
• Steven Mark Wenglowsky · Boulder, US
• Yulian Zhang · San Diego, US

Key dates

• Filing date: Feb 5, 2016
• Grant date: Feb 12, 2019
• Expiry date: Feb 5, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described herein are compounds, such as compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions, e.g., for treating a condition mediated by aberrant RET activity